1. Mattioli, AV, Manenti, A, Farinetti, A. Sex differences in adherence to guidelines in aspirin prescription in a population of low-risk cardiovascular patients. Eur J Prev Cardiol 2018; 25: 606–607.
Google Scholar | SAGE Journals | ISI2. Eindhoven, DC, Hilt, AD, Zwaan, TC, et al. Age and gender differences in medical adherence after myocardial infarction: women do not receive optimal treatment – the Netherlands claims database. Eur J Prev Cardiol 2018; 25: 181–189.
Google Scholar | SAGE Journals | ISI3. Bowman, L, Mafham, M, Wallendszus, K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379: 1529–1539.
Google Scholar | Crossref | Medline4. Janssen, VE, Visseren, FL, de Boer, A, et al. Combined use of polypill components in patients with type 2 diabetes mellitus. Eur J Prev Cardiol 2018; 25: 1523–1531.
Google Scholar | SAGE Journals | ISI5. Piepoli, MF, Hoes, AW, Agewall, S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315–2381.
Google Scholar | Crossref | Medline | ISI6. Pignone, M, Alberts, MJ, Colwell, JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010; 121: 2694–2701.
Google Scholar | Crossref | Medline | ISI7. Schwarzer G, Carpenter JR and Rücker G. Small-Study Effects in Meta-Analysis. In: Meta-Analysis with R. Cham: Springer International Publishing, 2015, pp. 107–141.
Google Scholar8. Early Treatment Diabetic Retinopathy Study Investigators . Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992; 268: 1292–1300.
Google Scholar | Crossref | Medline9. Belch, J, MacCuish, A, Campbell, I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840–a1840.
Google Scholar | Crossref | Medline10. Saito, Y, Okada, S, Ogawa, H, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation 2017; 135: 659–670.
Google Scholar | Crossref | Medline11. Steering Committee of the Physicians' Health Study Research Group. Final Report on the Aspirin Component of the Ongoing Physicians’ Health Study. N Engl J Med 1989; 321: 129–135.
Google Scholar12. Hansson, L, Zanchetti, A, Carruthers, SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (London, England) 1998; 351: 1755–1762.
Google Scholar | Crossref | Medline | ISI13. Sacco, M, Pellegrini, F, Roncaglioni, MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin e in type 2 diabetic patients. Results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264–3272.
Google Scholar | Crossref | Medline | ISI14. Ridker, PM, Cook, NR, Lee, I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–1304.
Google Scholar | Crossref | Medline | ISI15. Ikeda, Y, Shimada, K, Teramoto, T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312: 2510–2520.
Google Scholar | Crossref | Medline | ISI16. McNeil, JJ, Wolfe, R, Woods, RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018; 379: 1509–1518.
Google Scholar | Crossref | Medline17. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
Google Scholar18. Butalia, S, Leung, AA, Ghali, WA, et al. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol 2011; 10: 25–25.
Google Scholar | Crossref | Medline | ISI19. Kunutsor, SK, Seidu, S, Khunti, K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabet Med 2017; 34: 316–327.
Google Scholar | Crossref | Medline20. Kokoska, LA, Wilhelm, SM, Garwood, CL, et al. Aspirin for primary prevention of cardiovascular disease in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2016; 120: 31–39.
Google Scholar | Crossref | Medline